Life sciences · Interventional Study
ClinicalTrials.gov · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT02774759). This is a study registration, not published results. Lead sponsor: M.D. Anderson Cancer Center. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 15 participants (ACTUAL). Conditions: Malignant Neoplasms of Female Genital Organs. Interventions: DEVICE: Accelerometer; BEHAVIORAL: Questionnaires; BEHAVIORAL: Fitness Test; BEHAVIORAL: Resistance Training; BEHAVIORAL: Aerobic Exercise; BEHAVIORAL: Telephone Coaching/Phone Calls; BEHAVIORAL: Video Chat Sessions. Primary outcome measures: Feasibility of Two Home-Based Weight Loss Interventions for Endometrial Cancer Survivors , 6 months; Feasibility of Two Home-Based Weight Loss Interventions for Endometrial Cancer Survivors , 6 Months; Feasibility of Two Home-Based Weight Loss Interventions for Endometrial Cancer Survivors , 6 months; Feasibility of Two Home-Based Weight Loss Interventions for Endometrial Cancer Survivors , 6 months. Brief summary: The goal of this research study is to learn if a home-based physical activity program is feasible and can help endometrial cancer survivors lose weight.